Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Sunscreening Agents
Interventions: BAY987521; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Anthrax, Anthrax Immunisation
Interventions: AV7909; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: MDD
Interventions: Wellbutrin SR 300Mg Extended-Release Tablet; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: 2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection, Respiratory Distress Syndrome, Adult, Adult Respiratory Distress Syndrome
Interventions: USB002, Placebo; Drug
Lead sponsor: US Biotest, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Rotavirus Infection, Rotavirus Vaccines
Interventions: Rotarix, Pediarix, Hiberix, Prevenar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 47
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more

Conditions: Healthy Participants
Interventions: KT-621; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Adenovirus Disease
Interventions: Brincidofovir, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 3 Months to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more

Conditions: Posttraumatic Stress Disorder
Interventions: Case Formulation plus Cognitive Processing Therapy, Cognitive Processing Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Phoenix, Arizona • Honolulu, Hawaii • New Orleans, Louisiana + 5 more

Conditions: Sickle Cell Anemia
Interventions: Hydroxyurea; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 2 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • New York, New York + 3 more

Conditions: Healthy
Interventions: Treatment A: 400 mg Pacritinib P3CT, Treatment B: 400 mg of pacritinib FMI; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy Participants
Interventions: TEV-56286 Test, TEV-56286 Reference; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 30
States / cities: Orange, California • Sacramento, California • Aurora, Colorado + 22 more

Conditions: Nocturia
Interventions: Desmopressin Melt; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 64
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 54 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 36
States / cities: Artesia, California • La Jolla, California • Los Angeles, California + 31 more

Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Interventions: Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib, 5-Fluorouracil, Cisplatin, Paclitaxel, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 14
States / cities: Anchorage, Alaska • Duarte, California • Orange, California + 11 more

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: COVID-19
Interventions: ALG-097558, Dabigatran, Itraconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Allergic Asthma
Interventions: Omalizumab, Placebo, Asthma therapies; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 17 Years to 70 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 100
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Beverly Hills, California • Skokie, Illinois • Overland Park, Kansas + 9 more

Conditions: Allergic Rhinitis, Chronic Urticaria
Interventions: Levocetirizine 1.25 mg, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 6 Months to 11 Months
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more

Conditions: Bacterial Infections
Interventions: Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gastroesophageal Reflux Disease
Interventions: Dexlansoprazole MR, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 99
States / cities: Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 96 more

Conditions: Bipolar Disorder, Depression, Bipolar
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 60
States / cities: Chandler, Arizona • Litchfield Park, Arizona • Little Rock, Arkansas + 50 more

Search by objective public record fields.

Sun Protection Factor Assay (SPF Assay 205/2016)

Anthrax AV7909 Liquid vs Lyophilized

Effect of Bupropion on Seizure Threshold in Depressed Patients

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

A Study to Evaluate Different Oral Formulations of KT-621

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

A Case Formulation Approach to Cognitive Processing Therapy

Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

A Study to Assess New Formulations of TEV-56286

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Adjunctive Ziprasidone in the Treatment of Bipolar I Depression